In conclusion, we showed that serum CRBN, as the target protein of IMiDs, was associated with disease features, survival in MM patients treated with Lenalidomide, and responsiveness to therapy, making this protein crucial for MM patients receiving Lenalidomide. Here, CRBN is linked to Miyoshi myopathy.